Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein

Cancer Research

Volumn 61, Issue 6, 2001, Pages 2618-2624

  Shimizu, Koichi ^a   Thomas, Elaine K ^c   Giedlin, Martin ^d   Mulé, James J ^a,b  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^c AMGEN INC   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; FOREIGN HELPER PROTEIN; GAMMA INTERFERON; INTERLEUKIN 2; KEYHOLE LIMPET HEMOCYANIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CELL LYSATE; DENDRITIC CELL; DEPIGMENTATION; FEMALE; IMMUNE RESPONSE; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN METASTASIS; SURVIVAL; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS; CANCER VACCINES; DENDRITIC CELLS; FEMALE; H-2 ANTIGENS; HEMOCYANIN; INTERFERON TYPE II; INTRAMOLECULAR OXIDOREDUCTASES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; PEPTIDE FRAGMENTS; PHENOTYPE;

EID: 0035866803     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. + T cell help
2. The dendritic cell system and its role in immunogenicity
3. Dendritic cells: Unique leukocyte populations which control the primary immune response
4. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells
5. + T-cells from mice immunized to syngeneic sarcomas recognize distinct, non-shared tumor antigens
6. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo
7. Induction of antitumor immunity using bone marrow-generated dendritic cells
8. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
9. The human primary immune response to keyhole limpet hemocyanin: Interrelationships of delayed type hypersensitivity, antibody response, and in vitro blast transformation
10. The secondary immune response to keyhole limpet hemocyanin
11. Regulation of T helper cell differentiation in vivo by soluble and membrane proteins provided by antigen-presenting cells
12. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/ macrophage colony-stimulating factor primes mice for a protective T-cell response
13. Active specific immunotherapy with hapten-modified autologous melanoma cell vaccine
14. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
15. Vaccination of patients with B celt lymphoma using autologous antigen-pulsed dendritic cells
16. Therapeutic efficacy of T cells derived from lymph nodes draining a poorly immunogenic tumor transduced to secrete granulocyte-macrophage colony-stimulating factor
17. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
18. Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2
19. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2
20. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
21. + tumor-infiltrating lymphocytes
22. Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens
23. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings
24. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2
25. Immunomodulatory properties and toxicity of interleukin 2 in patients with cancer
26. MHC-restricted cytotoxic T celts: Studies on the biological role of polymorphic major transplantation antigens determining T-cell restriction-specificity, function, and responsiveness
27. Immunotherapy of a murine tumor with interleukin 2. Increased sensitivity after MHC class I gene transfection
28. Tumor necrosis factor enhances HLA-A, B, C and HLA-DR gene expression in human tumor cells
29. Modulation by recombinant DNA leukocyte (α) and fibroblast (β) interferons of the expression and shedding of HLA- and tumor-associated antigens by human melanoma cells
30. Modulation of murine tumor major histocompatibility antigens by cytokines in vivo and in vitro
31. Tumor immunity and autoimmunity induced by immunization with homologous DNA
32. + T lymphocytes
33. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
34. Antigen presentation by dendritic cells focuses T cell responses against immunodominant peptides: Studies in the hen egg-white lysozyme (HEL) model
35. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp 100 in HLA-A2 transgenic mice
36. + T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells
37. Natural cell-mediated cytotoxicity (NCMC) against NK-sensitive tumours in vitro by murine spleen Ly-6C+ natural T cells
38. Enhanced in vitro macrophage cytotoxicity against interferon-treated B16 melanoma cells
39. Enhanced in vivo sensitivity of in vitro interferon-treated B16 melanoma cells to CD8 cells and activated macrophages
40. T cell-mediated, IFN-γ-facilitated rejection of murine B16 melanomas
41. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma
42. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors
43. + T cells
44. Linkage of foreign carrier proteir to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine
45. Vaccine therapy of pediatric solid tumors with tumor lysate-pulsed dendritic cells